Pharsight

Cumberland Pharms patents expiration

1. Acetadote patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(1 year, 10 months from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(1 year, 10 months from now)

US8148356 CUMBERLAND PHARMS Acetylcysteine composition and uses therefor
May, 2026

(2 years from now)

US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof
Jul, 2031

(7 years from now)

US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(8 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

2. Caldolor patents expiration

CALDOLOR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen
Sep, 2030

(6 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprof...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

Family Patents

3. Vibativ patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6635618 CUMBERLAND PHARMS Glycopeptide phosphonate derivatives
Sep, 2023

(17 days ago)

US7531623 CUMBERLAND PHARMS Hydrochloride salts of a glycopeptide phosphonate derivative
Jan, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858584 CUMBERLAND PHARMS Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Aug, 2022

(1 year, 1 month ago)

Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 September, 2009

Treatment: Method for treating bacterial infection

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

VIBATIV family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic